Zentalis is already preparing for a potential U.S. launch of its WEE1 inhibitor azenosertib after encouraging ovarian cancer data at ESMO. CEO Julie Eastland tells Fierce why the biotech sees a commercial opportunity. fiercebiotech.com/biotech/esmo-z…#ESMO26
The U.S. Treasury is proposing new restrictions on investments in Chinese biotech, but traditional pharma licensing deals would largely be spared. Equity investments and certain partnerships could face significant hurdles.
Roche is building its blockbuster case for MS hopeful fenebrutinib, unveiling new data on brain lesions, disability progression and brain volume loss as the BTK inhibitor advances toward an FDA decision.
After a turbulent period at the FDA, CBER Director Karim Mikhail tells Fierce he's focused on restoring stability, rebuilding morale and rethinking rare disease regulation. "I'm not going to hide," he said.